Outsourcing Pharma

41. Drug Delivery Systems' Increasing Role In Patient Outcomes: What's Next? 3/1/2021

    The role of DDS providers to pharma evolved from transactional suppliers to innovation partners, and the-yet-to-be-met promises of IoMT place them more and more at the center of attention. 

42. 4 Qualities Of Effective Project Managers At Contract Service Organizations 3/1/2021

    We examine how certain behaviors and actions impact a contractor-sponsor relationship and what a project manager can do to provide the best services possible to the sponsor/client.

43. What Makes Outsourcers Very Satisfied? 10/1/2020

    Would you give your CDMO a 10/10 for overall satisfaction? Data from ISR’s Biologic API and Biologic Drug Product CMO Quality Benchmarking reports show only 3 percent of service interactions result in top scores. Learn what made some biologic outsourcers very satisfied with their CDMO experience and what these sponsor-CDMO relationships have in common. 

44. PPA Differences Between Small And Large Sponsors 10/1/2020

    The overwhelming majority of small and emerging biopharma companies do not have preferred provider agreements (PPAs) for Phase 2/3 outsourcing. What does this mean?

45. The Global Regulatory And Quality Environment For Biopharma Outsourcing 8/17/2020

    It is critical that organizations looking to engage an external contract service provider be aware of new regulations to align their programs with the latest expectations for each relevant market.

46. A Shared Methodology Between A Sponsor And CMO To Mitigate Stigma 4/1/2020

    Collaborative efforts made by the sponsor and the CMO, coupled with a well-defined process grounded in design thinking, can lead to improved patient compliance.

47. Outsourcing Success Requires Constant Evolution 4/1/2020

    Industry Standard Research explains how Life Science Leader’s CMO Leadership Awards and the corresponding market research data can be used by biopharma companies to make more informed CMO selection decisions and by contract manufacturers to optimize operational and marketing strategies.

48. What's Wrong With A Transactional Relationship With Your Contractor? 4/1/2020

    A deal between firms is necessarily an alignment of interests, at least over the term of the deal. There should be no expectation that the interests of two firms will be constant over time or that they will always be able to make a deal or collaborate.

49. Award-Winning Questions: “Who Are We?” And “Who Are They?” 4/1/2020

    Outsourcing Pharma Chief Editor Louis Garguilo explains what you can expect from this year’s CMO Awards publication and how it can help you when choosing an outsourcing partner.

50. Overcoming The Challenges Of Patient-Centric Specification Setting 4/1/2020

    The revolution in scientific knowledge that is bringing hope to patients with devastating diseases is also setting the stage for modernizing our approach to specifications and process control. Updating our approach to specification setting will accelerate the delivery of breakthroughs to patients.